BLS.AU Bls Pharmaceuticals Limited
- Market cap
- AUD 242M
- P/E
- 14.6x
- P/B
- 7.78x
- ROE
- 49.5%
- Dividend yield
- -
- Fundamental score
- 2.1/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is BLS.AU undervalued?
Graham numberBLS.AU trades 125.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bls Pharmaceuticals Limited fundamental analysis
9 of 22 checks passedROE 2/2
High return on equity (49.5%), above 20%.
ROA 1/1
Return on assets (29.6%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Earnings growth cannot be compared with the industry.
Revenue Growth 2/2
Revenue grew 143.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (6.2%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 34.0x against interest expense, well covered.
PE vs Market 1/1
PE (14.6x) is below the market median (15.0x).
PE vs Industry 1/1
PE (14.6x) is below the industry median (16.3x).
PBV 0/1
Price to book (7.8x) is above the industry median (4.4x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 114.0, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Bls Pharmaceuticals Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bls Pharmaceuticals Limited
BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments. The Manufacture/Sales Australia segment engages in the manufacture and wholesale supply of preventive and novel medicines, cannabis, psilocybin, and MDMA under BLS. The Plant Based/UK/EU/JPN/AUS segmen…
Full company profileBls Pharmaceuticals Limited financial statements
Bls Pharmaceuticals Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 2.42M | 5.16M | 9.33M | 74.2M |
| Gross Profit | 1.29M | 1.90M | 3.40M | 41.6M |
| Operating Income | -258K | -2.14M | -1.66M | 15.8M |
| EBITDA | - | -2.05M | -1.66M | 17.0M |
| Net Income | -237K | -1.96M | -13.3M | 15.4M |
| EPS | 0.00 | -0.01 | -0.07 | 0.07 |
| Balance Sheet | ||||
| Total Assets | 2.92M | 17.7M | 6.70M | 52.1M |
| Total Liabilities | 982K | 2.69M | 3.40M | 21.0M |
| Shareholders' Equity | 1.89M | 15.1M | 3.61M | 31.1M |
| Cash & Short-term Investments | 2.17M | 3.85M | 1.03M | 13.3M |
| Cash Flow | ||||
| Capital Expenditure | 5.79K | 58.6K | 493K | 3.46M |
| Free Cash Flow | 429K | -1.19M | -4.09M | 1.95M |
| Ratios | ||||
| ROE | -12.5% | -13.0% | -369.5% | 49.5% |
| ROA | -8.1% | -11.1% | -199.0% | 29.6% |
| Net Profit Margin | -9.8% | -38.1% | -142.9% | 20.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bls Pharmaceuticals Limited dividends
Bls Pharmaceuticals Limited has not paid dividends in the last 4 fiscal years.
Last stock split: 1:10 on Jun 24, 2026.
Who owns Bls Pharmaceuticals Limited
- Insiders 52.32%
- Institutions 0.73%
- Public & others 46.95%
- Shares outstanding 236M
- Free float 62.5M
Bls Pharmaceuticals Limited company profile
- Company name
- Bls Pharmaceuticals Limited
- Ticker
- BLS.AU
- ISIN
- AU0000477796
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Level 5, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9078 8180
- Website
- blspharma.com
About Bls Pharmaceuticals Limited
BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments. The Manufacture/Sales Australia segment engages in the manufacture and wholesale supply of preventive and novel medicines, cannabis, psilocybin, and MDMA under BLS. The Plant Based/UK/EU/JPN/AUS segment manufactures and distributes consumer health and novel food products under the Dr Watson brand. The Wholesale PCC/USA segment is involved in wholesale of patented Probiotics for gastrointestinal health and immunity. It also provides contract manufacturing services; and storage and distribution services. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited is headquartered in Sydney, Australia.
Bls Pharmaceuticals Limited management
3- Mr. Samuel WatsonCEO, MD & Executive Director
- Mr. Jason HineCOO & Executive Director
- Macdarragh O'NeillHead of Production of GMP & Director of BLS Wholesalers Pty